Lipoprotein-associated phospholipase A₂, and subsequent cardiovascular events and mortality among patients with coronary heart disease

References

• Allison MA, Denenberg JO, Nelson JJ, et al. (2007). The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients. J Vasc Surg 46:500–6.
   PubMed Web of Science ®Google Scholar
• Brilakis EM, Khera A, MGuire DK, et al. (2008). Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart study. Atherosclerosis 199:110–15.
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–97.
   PubMed Web of Science ®Google Scholar
• Garg PK, McClelland RL, Jenny NS, et al. (2015). Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: the multi ethnic study of atherosclerosis. Atherosclerosis 241:176–82.
   PubMed Web of Science ®Google Scholar
• Gazi I, Lourida ES, Filippatos T, et al. (2005). Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 51:2264–73.
   PubMed Web of Science ®Google Scholar
• Gerber Y, Dunlay SM, Jaffe AS, et al. (2009). Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community. Atherosclerosis 203:593–8.
   PubMed Web of Science ®Google Scholar
• Goldbourt U, Behar S, Reicher-Reiss H, et al. for the Bezafibrate Infarction Prevention Study Group. (1993). Rationale and design of a secondary prevention trial of increasing serum HDL cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease. Am J Cardiol 71:909–15.
   PubMed Web of Science ®Google Scholar
• Grallert H, Dupuis J, Bis JC, et al. (2012). Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J 33:238–51.
   PubMed Web of Science ®Google Scholar
• Harrell FE, Lee KL, Mark DB. (1996). Tutorial in biostatistics: multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–87.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. (2010). Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med 268:348–58.
   PubMed Web of Science ®Google Scholar
• Johnson JL, Shi Y, Snipes R, et al. (2014). Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial. PLoS One 9:e89034.
   Web of Science ®Google Scholar
• Karabina SA, Gora S, Atout R, Ninio E. (2010). Extracellular phospholipases in atherosclerosis. Biochimie 92:594–600.
   PubMed Web of Science ®Google Scholar
• Koenig W, Twardella D, Brenner H, Rothenbacher D. (2006). Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 26:1586–93.
   PubMed Web of Science ®Google Scholar
• Lee KK1, Fortmann SP, Varady A, et al. (2011). Racial variation in lipoprotein-associated phospholipase A2 in older adults. BMC Cardiovasc Disord 11:38.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM. (2006). Inflammation and atherothrombosis: from population biology and bench research to clinical practice. J Am Coll Cardiol 48:A33–46.
   Web of Science ®Google Scholar
• Maiolino G, Pedon L, Cesari M, et al. (2012). Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. PLoS One 7:e48171.
   Google Scholar
• Mallat Z, Lambeau G, Tedgui A. (2010). Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 122:2183–200.
   PubMed Web of Science ®Google Scholar
• May S, Hosmer DW. (1998). A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 4:109–20.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. (2002). K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1e266.
   Google Scholar
• O'donoghue ML, Braunwald E, White HD, et al. for the SOLID-TIMI 52 Investigators. (2014). Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 312:1006.
   PubMed Web of Science ®Google Scholar
• Oei HH, van der Meer IM, Hofman A, et al. (2005). Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 111:570–5.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'agostino RB Sr, D'agostino RB Jr, Vasan RS. (2008). Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–72.
   PubMed Web of Science ®Google Scholar
• Robins SJ, Collins D, Nelson JJ, et al. (2008). Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 28:1172–8.
   PubMed Web of Science ®Google Scholar
• Rosenson RS. (2008). Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J 155:499.e9–16.
   PubMed Web of Science ®Google Scholar
• Saougos VG, Tambaki AP, Kalogirou M, et al. (2007). Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 27:2236–43.
   PubMed Web of Science ®Google Scholar
• Serruys PW, García-García HM, Buszman P, et al. for the Integrated Biomarker and Imaging Study-2 Investigators. (2008). Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118:1172–82.
   PubMed Web of Science ®Google Scholar
• The BIP Study Group. (2000). Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102:21–7.
   PubMed Web of Science ®Google Scholar
• The LP-PLA2 Studies Collaboration. (2010). Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality. Lancet 375:1536–44.
   PubMed Web of Science ®Google Scholar
• White HD, Simes J, Stewart RA, et al. LIPID Study Investigators. (2013). Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. J Am Heart Assoc 2:e000360.
   Web of Science ®Google Scholar
• White HD, Held C, Stewart R, et al. STABILITY Investigators. (2014). Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 370:1702–11.
   PubMed Web of Science ®Google Scholar